The report, which surveyed over 50 senior executives at global pharmaceutical and biotech firms, reveals that pre-trial preparation—including synopses, case report forms, and protocol development—often consumes up to eight weeks for more than half of all sponsors. These initial delays only worsen as trials progress; nearly 76% of organizations juggle three or more vendors, creating disjointed workflows that stall critical-path statistical programming.

Financial burdens scale aggressively alongside this complexity. While post-trial workflow spending sits at roughly $250,000 for Phase I studies, that figure balloons to $900,000 by Phase III. With industry estimates valuing the cost of daily trial delays between $600,000 and $8 million, these multi-week reporting bottlenecks represent a significant vulnerability. Raviv Pryluk, CEO of PhaseV, argues that the current reliance on manual, sequential handoffs is a broken model that necessitates a shift toward integrated, AI-driven automation to ensure regulatory readiness and faster patient access.